Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction

Journal of Experimental Medicine

Volumn 203, Issue 9, 2006, Pages 2165-2175

  Girardi, Guillermina ^a   Yarilin, Dmitry ^a   Thurman, Joshua M ^b   Holers, V Michael ^b   Salmon, Jane E ^a  

^a Department of Obstetrics Gynecology   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; COMPLEMENT COMPONENT C5A; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STIMULATION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; FEMALE; FETUS DISEASE; GROWTH INHIBITION; IMMUNE RESPONSE; INFLAMMATORY INFILTRATE; MALE; MONOCYTE; MOUSE; NONHUMAN; PLACENTA DEVELOPMENT; PLACENTA DISORDER; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL GROWTH; PRENATAL INJURY; PRIORITY JOURNAL; PROTEIN SECRETION; SPONTANEOUS ABORTION;

ABORTION, SPONTANEOUS; ANGIOGENESIS INDUCING AGENTS; ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT C5A; EMBRYO; FEMALE; FETAL GROWTH RETARDATION; FETUS; HUMANS; MACROPHAGES; MALE; MICE; MICE, INBRED STRAINS; MONOCYTES; PLACENTA; PLACENTA DISEASES; PLACENTAL INSUFFICIENCY; PREGNANCY; PREGNANCY COMPLICATIONS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 33748450585     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20061022     Document Type: Article

References (54)

1. Mills, J.L., J.L. Simpson, S.G. Driscoll, L. Jovanovic-Peterson, M. Van Allen, J.H. Aarons, B. Metzger, F.R. Bieber, R.H. Knopp, L.B. Holmes, et al. 1988. Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception. N. Engl. J. Med. 319:1617-1623.
2. Resnik, R., and R.K. Creasy. 2003. Intrauterine growth restriction. In Maternal-Fetal Medicine: Principles and Practice. J.D. Iams, editor. Saunders, Philadelphia. 495-512.
3. Godfrey, K.M., and D.J. Barker. 2000. Fetal nutrition and adult disease. Am. J. Clin. Nutr. 71:1344S-1352S.
4. Mellor, A.L., and D.H. Munn. 2000. Immunology at the maternal-fetal interface: lessons for T cell tolerance and suppression. Annu. Rev. Immunol. 18:367-391.
5. Hunt, J.S., M.G. Petroff, R.H. McIntire, and C. Ober. 2005. HLA-G and immune tolerance in pregnancy. FASEB J. 19:681-693.
6. Guleria, I., A. Khosroshahi, M.J. Ansari, A. Habicht, M. Azuma, H. Yagita, R.J. Noelle, A. Coyle, A.L. Mellor, S.J. Khoury, and M.H. Sayegh. 2005. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J. Exp. Med. 202:231-237.
7. Xu, C., D. Mao, V.M. Holers, B. Palanca, A.M. Cheng, and H. Molina. 2000. A critical role for murine complement regulator crry in fetomaternal tolerance. Science. 287:498-501.
8. Aluvihare, V.R., M. Kallikourdis, and A.G. Betz. 2004. Regulatory T cells mediate maternal tolerance to the fetus. Nat. Immunol. 5:266-271.
9. Mellor, A.L., J. Sivakumar, P. Chandler, K. Smith, H. Molina, D. Mao, and D.H. Munn. 2001. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat. Immunol. 2:64-68.
10. Caucheteux, S.M., C. Kanellopoulos-Langevin, and D.M. Ojcius. 2003. At the innate frontiers between mother and fetus: linking abortion with complement activation. Immunity. 18:169-172.
11. Holers, V.M., G. Girardi, L. Mo, J.M. Guthridge, H. Molina, S.S. Pierangeli, R. Espinola, L.E. Xiaowei, D. Mao, C.G. Vialpando, and J.E. Salmon. 2002. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J. Exp. Med. 195:211-220.
12. Girardi, G., J. Berman, P. Redecha, L. Spruce, J.M. Thurman, D. Kraus, T.J. Hollmann, P. Casali, M.C. Caroll, R.A. Wetsel, et al. 2003. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J. Clin. Invest. 112:1644-1654.
13. Red-Horse, K., Y. Zhou, O. Genbacev, A. Prakobphol, R. Foulk, M. McMaster, and S.J. Fisher. 2004. Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface. J. Clin. Invest. 114:744-754.
14. Lam, C., K.H. Lim, and S.A. Karumanchi. 2005. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension. 46:1077-1085.
15. Ferrara, N., H.P. Gerber, and J. LeCouter. 2003. The biology of VEGF and its receptors. Nat. Med. 9:669-676.
16. Kendall, R.L., and K.A. Thomas. 1993. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA. 90:10705-10709.
17. He, Y., S.K. Smith, K.A. Day, D.E. Clark, D.R. Licence, and D.S. Charnock-Jones. 1999. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol. Endocrinol. 13:537-545.
18. Eubank, T.D., R. Roberts, M. Galloway, Y. Wang, D.E. Cohn, and C.B. Marsh. 2004. GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice. Immunity. 21:831-842.
19. Krysiak, O., A. Bretschneider, E. Zhong, J. Webb, H. Hopp, S. Verlohren, N. Fuhr, M. Lanowska, A. Nonnenmacher, R. Vetter, et al. 2005. Soluble vascular endothelial growth factor receptor-1 (sFLT-1) mediates downregulation of FLT-1 and prevents activated neutrophils from women with preeclampsia from additional migration by VEGF. Circ. Res. 97:1253-1261.
20. Maynard, S.E., J.Y. Min, J. Merchan, K.H. Lim, J. Li, S. Mondal, T.A. Libermann, J.P. Morgan, F.W. Sellke, I.E. Stillman, et al. 2003. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111:649-658.
21. Charnock-Jones, D.S., and G.J. Burton. 2000. Placental vascular morphogenesis. Baillieres Best Pract. Res. Clin. Obstet. Gynaecol. 14:953-968.
22. Levine, R.J., S.E. Maynard, C. Qian, K.H. Lim, L.J. England, K.F. Yu, E.F. Schisterman, R. Thadhani, B.P. Sachs, F.H. Epstein, et al. 2004. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350:672-683.
23. Zhou, Y., M. McMaster, K. Woo, M. Janatpour, J. Perry, T. Karpanen, K. Alitalo, C. Damsky, and S.J. Fisher. 2002. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am. J. Pathol. 160:1405-1423.
24. De Bandt, M., M.H. Ben Mahdi, V. Ollivier, M. Grossin, M. Dupuis, M. Gaudry, P. Bohlen, K.E. Lipson, A. Rice, Y. Wu, et al. 2003. Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis. J. Immunol. 171:4853-4859.
25. Nozaki, M., B.J. Raisler, E. Sakurai, J.V. Sarma, S.R. Barnum, J.D. Lambris, Y. Chen, K. Zhang, B.K. Ambati, J.Z. Baffi, and J. Ambati. 2006. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc. Natl. Acad. Sci. USA. 103:2328-2333.
26. Bora, P.S., J.H. Sohn, J.M. Cruz, P. Jha, H. Nishihori, Y. Wang, S. Kaliappan, H.J. Kaplan, and N.S. Bora. 2005. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J. Immunol. 174:491-497.
27. Rajakumar, A., H.M. Michael, P.A. Rajakumar, E. Shibata, C.A. Hubel, S.A. Karumanchi, R. Thadhani, M. Wolf, G. Harger, and N. Markovic. 2005. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta. 26:563-573.
28. Clark, D.A., G. Chaouat, P.C. Arck, H.W. Mittruecker, and G.A. Levy. 1998. Cytokine-dependent abortion in CBA x DBA/2 mice is mediated by the procoagulant fgl2 prothrombinase. J. Immunol. 160:545-549.
29. Blois, S., M. Tometten, J. Kandil, E. Hagen, B.F. Klapp, R.A. Margni, and P.C. Arck. 2005. Intercellular adhesion molecule-1/LFA-1 cross talk is a proximate mediator capable of disrupting immune integration and tolerance mechanism at the feto-maternal interface in murine pregnancies. J. Immunol. 174:1820-1829.
30. Kim, Y.U., T. Kinoshita, H. Molina, D. Hourcade, T. Seya, L.M. Wagner, and V.M. Holers. 1995. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J. Exp. Med. 181:151-159.
31. Wang, Y., S.A. Rollins, J.A. Madri, and L.A. Matis. 1995. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. USA. 92:8955-8959.
32. Strachan, A.J., T.M. Woodruff, G. Haaima, D.P. Fairlie, and S.M. Taylor. 2000. A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats. J. Immunol. 164:6560-6565.
33. Higginbottom, A., S.A. Cain, T.M. Woodruff, L.M. Proctor, P.K. Madala, J.D. Tyndall, S.M. Taylor, D.P. Fairlie, and P.N. Monk. 2005. Comparative agonist/antagonist responses in mutant human C5a receptors define the ligand binding site. J. Biol. Chem. 280:17831-17840.
34. Sundsmo, J.S., J.R. Chin, R.A. Papin, D.S. Fair, and Z. Werb. 1985. Factor B, the complement alternative pathway serine proteinase, is a major constitutive protein synthesized and secreted by resident and elicited mouse macrophages. J. Exp. Med. 161:306-322.
35. Heeger, P.S., P.N. Lalli, F. Lin, A. Valujskikh, J. Liu, N. Muqim, Y. Xu, and M.E. Medof. 2005. Decay-accelerating factor modulates induction of T cell immunity. J. Exp. Med. 201:1523-1530.
36. Thurman, J.M., D.M. Kraus, G. Girardi, D. Hourcade, H.J. Kang, P.A. Royer, L.M. Mitchell, P.C. Giclas, J. Salmon, G. Gilkeson, and V.M. Holers. 2005. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol. Immunol. 42:87-97.
37. Girardi, G., P. Redecha, and J.E. Salmon. 2004. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat. Med. 10:1222-1226.
38. Hunt, J.S., H.L. Chen, and L. Miller. 1996. Tumor necrosis factors: pivotal components of pregnancy? Biol. Reprod. 54:554-562.
39. Berman, J., G. Girardi, and J.E. Salmon. 2005. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J. Immunol. 174:485-490.
40. Hung, T.H., D.S. Charnock-Jones, J.N. Skepper, and G.J. Burton. 2004. Secretion of tumor necrosis factor-alpha from human placental tissues induced by hypoxia-reoxygenation causes endothelial cell activation in vitro: a potential mediator of the inflammatory response in preeclampsia. Am. J. Pathol. 164:1049-1061.
41. Arck, P.C., A.B. Troutt, and D.A. Clark. 1997. Soluble receptors neutralizing TNF-alpha and IL-1 block stress-triggered murine abortion. Am. J. Reprod. Immunol. 37:262-266.
42. Knofler, M., B. Mosl, S. Bauer, G. Griesinger, and P. Husslein. 2000. TNF-alpha/TNFRI in primary and immortalized first trimester cytotrophoblasts. Placenta. 21:525-535.
43. Kraut, N., L. Snider, C.M. Chen, S.J. Tapscott, and M. Groudine. 1998. Requirement of the mouse I-mfa gene for placental development and skeletal patterning. EMBO J. 17:6276-6288.
44. Cross, J.C. 2005. How to make a placenta: mechanisms of trophoblast cell differentiation in mice - a review. Placenta. 26:S3-S9.
45. Patterson, C., M.A. Perrella, W.O. Endege, M. Yoshizumi, M.E. Lee, and E. Haber. 1996. Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. J. Clin. Invest. 98:490-496.
46. Rote, N.S., E. Vogt, G. DeVere, A.R. Obringer, and A.K. Ng. 1998. The role of placental trophoblast in the pathophysiology of the antiphospholipid antibody syndrome. Am. J. Reprod. Immunol. 39:125-136.
47. Rodesch, F., P. Simon, C. Donner, and E. Jauniaux. 1992. Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy. Obstet. Gynecol. 80:283-285.
48. Carroll, M.C., and V.M. Holers. 2005. Innate autoimmunity. Adv. Immunol. 86:137-157.
49. Fujita, T., M. Matsushita, and Y. Endo. 2004. The lectin-complement pathway - its role in innate immunity and evolution. Immunol. Rev. 198:185-202.
50. Jordan, J.E., M.C. Montalto, and G.L. Stahl. 2001. Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation. 104:1413-1418.
51. Mao, D., X. Wu, C. Deppong, L.D. Friend, G. Dolecki, D.M. Nelson, and H. Molina. 2003. Negligible role of antibodies and C5 in pregnancy loss associated exclusively with C3-dependent mechanisms through complement alternative pathway. Immunity. 19:813-822.
52. Gordon, S. 2003. Alternative activation of macrophages. Nat. Rev. Immunol. 3:23-35.
53. Takai, T., M. Li, D. Sylvestre, R. Clynes, and J.V. Ravetch. 1994. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell. 76:519-529.
54. Hopken, U.E., B. Lu, N.P. Gerard, and C. Gerard. 1996. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature. 383:86-89.